Full Text View
Tabular View
No Study Results Posted
Related Studies
Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome
This study has been completed.
Study NCT00001966   Information provided by National Institutes of Health Clinical Center (CC)
First Received: January 18, 2000   Last Updated: March 3, 2008   History of Changes

January 18, 2000
March 3, 2008
January 2000
 
 
 
Complete list of historical versions of study NCT00001966 on ClinicalTrials.gov Archive Site
 
 
 
Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome
A Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos Syndrome

This study will assess the effectiveness of mind-body therapy in relieving pain in patients with Ehlers-Danlos syndrome. This syndrome is a hereditary condition caused by a connective tissue defect and is often associated with chronic pain poorly controlled by medication or physical therapy. Mind-body therapy comprises various complementary or alternative medicine techniques such as meditation, guided imagery, stress management, and group psychotherapy.

Adult patients with Ehlers-Danlos syndrome who have chronic pain may be eligible for this 4 1/2 [Note: if the symbol is unreadable, it is four and one-half] to 5-month study. Patients not already enrolled in NHGRI's protocol 97-HG-0089 will undergo a history, physical examination, and brief interview before being accepted. Participants will attend 2-hour group sessions of mind-body therapy at NIH each week for at least 10 weeks. They will receive training in meditation, yoga breathing, guided imagery, and stress management in these sessions and will be asked to also practice the treatments at home each day. Patients may continue their regular medications and pain treatment with their private physicians during the course of the study.

Participants will fill out a packet of questionnaires about their pain, health, and quality of life at three intervals: when they enroll in the study, at the end of treatment, and 12 weeks after treatment ends. At these same time intervals, patients will come to NIH for a test of their physical ability to walk and climb stairs. Patients will keep a diary and pain symptoms and medications for 1 week before treatment begins and 1 week after it ends, and will fill out questionnaires about pain during the entire study period.

Ehlers-Danlos Syndrome (EDS) encompasses a spectrum of connective tissue diseases thought to result from defects in collagen formation. People with EDS are often affected by chronic, progressive pain poorly responsive to conventional treatment. We propose to investigate the efficacy of mind-body therapy for treatment of chronic pain in Ehlers-Danlos Syndrome. A cohort of adult subjects will be treated with mind-body therapy in a pilot study to assess the efficacy and acceptability of this treatment modality. The primary outcome measure will be change in pain as scored with a standardized inventory. We will also evaluate general health status, psychological variables, medication usage, and physical performance abilities.

Phase II
Interventional
Treatment, Safety/Efficacy Study
  • Ehlers-Danlos Syndrome
  • Pain
Drug: Mind-body therapy
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
40
January 2001
 

Clinical diagnosis of classical or hypermobile EDS based on history and physical examination by a study investigator.

Subjectively suffer from chronic pain (defined as pain occurring at least weekly).

Must agree to not seek mind-body therapy or other similar interventions outside of this study during the time under investigation.

Able to give informed consent.

No minors (under 18 years of age).

Not currently using formal mind-body or similar therapy for treatment of chronic pain.

No major surgical procedure within 90 days or intending to undergo such a procedure during the time course of this study.

Not decisionally impaired subjects.

No previous diagnosis or hospitalization for a psychotic condition(s). Specifically, no history of illness involving altered perception of reality. Psychiatric diagnoses such as depression or anxiety will not exclude participation.

Both
 
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00001966
 
000054, 00-HG-0054
National Human Genome Research Institute (NHGRI)
 
 
National Institutes of Health Clinical Center (CC)
January 2000

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP